Navigation Links
Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control


Beth Wegerbauer
Contributing Editor

According to the American Diabetes Association, the total annual economic cost of diabetes in 2002 was estimated to be $132 billion, or one out of every 10 health care dollars spent in the United States. A chronic disease with no cure, diabetes is a group of diseases (including Type 1, Type 2, and gestational) marked by high levels of blood glucose resulting from defects in insulin production, insulin action, or both. Nearly 20 million Americans have diabetes and nearly one-third of them don't even know it.

To combat this problem, the U.S. Department of Health and Human Services launched the Diabetes Detection Initiative to find this undiagnosed population through increased testing. Early diagnosis means that early steps can be taken to manage the disease and to prevent or delay complications.

The American Diabetes Association (ADA) recommends the hemoglobin A1C test, or HbA1c, as the best way to determine a patient's blood glucose control over the past 2-3 months. Specifically, the test measures the concentration of glycosylated hemoglobin. A1C levels are measured upon diagnosis, and, depending on a patient's type of diabetes, how well it is controlled, and his or her health-care provider, levels may be measured two to four times per year. Determining blood glucose control through this laboratory testing gives health-care providers the data they need to monitor the disease and to recommend appropriate treatment. Results from a major diabetes study, the Diabetes Control and Complications Trial (DCCT), confirm this test's importance. The study showed that lowering the HbA1c number can potentially reduce the development of complications and that lowering HbA1c levels by any amount improves a person's chances of staying healthy.

All HbA1c tests are not the same, but there is an ongoing international effort to standardize them by organizations like the National Glycoh
'"/>




Page: 1 2 3

Related medicine technology :

1. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
2. Tight Glycemic Control in the ICU
3. Controlling the Spread of Healthcare Associated Methicillin Resistant Staphylococcus aureus Requires Active Surveillance
4. New Quality Control Systems for Every Laboratory Application
5. Optimizing Quality Control Data Management
Post Your Comments:
(Date:12/1/2008)...ewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (...t , one of the world,s leading medical journals, r...egulator, experimental compound tasimelteon (VEC-1...titled "Melatonin agonist tasimelteon (VEC-162) fo...andomised controlled multicentre trials." Results ...
(Date:12/1/2008)...swire/ -- Roche announced today that a,comparativ...ived pain and,discomfort associated with blood gl...toring systems and lancing devices were deemed lea...ll, the ACCU-CHEK Aviva and ACCU-CHEK Compact,Plu...EK Multiclix, ACCU-CHEK,Softclix and ACCU-CHEK So...
(Date:12/1/2008)...he best policy , , ROCHESTER, Minn., Dec. ... Clinic finds the use of the drug therapy etanerce... acute inflammation of the liver caused by excessi...y are published in the December issue of Gastroen... , VIDEO ALERT: Additional audio and video res...
(Date:12/1/2008)...d for Tuesday, December 9 at 11:00 am ET to Discus...H SAN FRANCISCO, Calif., Dec. 1 /PRNewswire-Firs... SNSS ), a biopharmaceutical company focused on th...y therapeutics, today announced new data from its ...L) will be presented during the 50th American Soci...
Breaking Medicine Technology:Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful 2Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful 3Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 2Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 3ASPH and APHA Collaborate to Shore up the Public Health Workforce Pipeline 3A 27906 1ASPH and APHA Collaborate to Shore up the Public Health Workforce Pipeline 3A 27906 2ASPH and APHA Collaborate to Shore up the Public Health Workforce Pipeline 3A 27906 3Bright Horizons Congratulates 76 Clients Named to Working Mothers 100 Best 27901 1Bright Horizons Congratulates 76 Clients Named to Working Mothers 100 Best 27901 2Premier Research Honored as Clinical Research Team of the Year at 2008 GCPj Awards 3355 1Premier Research Honored as Clinical Research Team of the Year at 2008 GCPj Awards 3355 2Scientists unveil mechanism for up and down in plants 5605 1Scientists unveil mechanism for up and down in plants 5605 2
...etary DNA delivery technology enables sustained,In...es,atherosclerosis progression in mouse model of h..., 2007 - Research conducted,at Cleveland Clinic an...ology,s 58th Annual Scientific Session showed that...inflammatory protein,interferon-beta (IFN-beta) us...
...oadministered with statins for only five weeks at,...hieved with,statins alone, with similarly favorabl... and CARLSBAD, Calif., March 26, 2007,/PRNewswire-... new,results from its Phase 2 clinical trial of IS...day at the of Cardiology,Annual Scientific Session...
Other Medicine Technology:Interferon Beta DNA Treatment Delivered with Ichor Technology,Reduces Atherosclerosis Progression in Mice 2Interferon Beta DNA Treatment Delivered with Ichor Technology,Reduces Atherosclerosis Progression in Mice 3Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 2Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 3Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 4Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 5Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 6Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 7Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 8Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 9
(Date:12/2/2008)...N, China, Dec. 2 /PRNewswire-Asia-FirstCall/ -- Ch..." or "the Company") (Nasdaq: CSKI ), a leading,...over-the-counter drugs in,the People,s Republic o...Stanley) Hao was appointed Chief Financial Officer...,s Board of Directors. He replaces Yu-kun Zhang, ...
(Date:12/2/2008)...BURGH, Dec. 2 Mylan Inc....ubsidiary, Mylan Pharmaceuticals Inc., have entere...aceuticals Corp., Novartis,Corp. and Novartis Int...neric,version of Novartis, Femara(R). , My...ted: "We are very,pleased to have reached this ag...
(Date:12/2/2008)...NVILLE, Calif., Dec. 2 In response...n A Toxicity, Frequent Respiratory Infections, and...ovember 11th by 16 well known supplement experts, ... oil products pose no threat or compromise to cons...solutions that are low in natural Vitamin A. Accor...
(Date:12/2/2008)... SPEAK to collect and dissemin... Bellevue, Wash. (PRWEB) December ...ced the launch of a new initiative to focus public...eness . The official kick-off of SPEAK will occur ...acists (ASHP) 2008 Midyear Clinical Meeting, to be...
Breaking Medicine News(10 mins):Health News:China Sky One Medical, Inc. Appoints Yu-bo Hao as CFO 2Health News:China Sky One Medical, Inc. Appoints Yu-bo Hao as CFO 3Health News:Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity 2Health News:Nordic Naturals Offers Cod Liver Oil Solutions in Response to Recent Vitamin A and Vitamin D Controversy 2Health News:Pharmacy OneSource Launches SPEAK Initiative to Promote Medication Safety Awareness 2
...ave limited benefit in the first-line treatment of...// according to a report in the April issue of Arc...rnals. However, a second report in the same issue ...may be effective in patients with another ulcer-ca...
...n (FDA) is alerting consumers to possible serious ...aminated with a deadly bacterium, Clostridium botu...lly fatal illness. The olives are made by Charlie ... and are being recalled by the manufacturer. No il...
...for liver cancer, says a US study. Using DNA isol... researchers at Columbia University's Mailman Scho...rly detection of liver cancer, says the study publ...of Clinical Cancer Research. The scientists exami...
...ke is an effective way of identifying prostate can...teoporosis, according to a research.// Researcher... Barcelona, Spain, looked at a cross-section of 37...t were receiving androgen-deprivation therapy (ADT...
Other Medicine News:Health News:Clinical Studies Evaluate Potential Treatments for Mouth Ulcers 2Health News:Clinical Studies Evaluate Potential Treatments for Mouth Ulcers 3Health News:FDA Urgently Warns Consumers About Health Risks of Potentially Contaminated Olives 2Health News:Blood DNA Predicts Liver Cancer Early 2Health News:Measuring Calcium Intake Help to Identify Osteoporosis in Prostate Cancer Patient 2
...ducts are offered as 1-piece or modular, in regula...ay be customized with handles of choice and other ...ts. Many standard patterns are available from Medi...ivery times. , Please Note: Individual instrumen...
...ducts are offered as 1-piece or modular, in regula...ay be customized with handles of choice and other ...ts. Many standard patterns are available from Medi...ivery times. , Please Note: Individual instrumen...
...ducts are offered as 1-piece or modular, in regula...ay be customized with handles of choice and other ...ts. Many standard patterns are available from Medi...ivery times. , Please Note: Individual instrumen...
The Featured Products are kept in stock at Mediflex and are offered as 1-piece or modular in regular or extra long lengths. All come equipped with insulation, flush ports, rotating shafts, ratchets (
Medicine Products: